Name: Bcal Diagnostics (BDX) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

BDX

Pharmaceuticals, Biotechnology & Life Sciences

Bcal Diagnostics

Short interest: 0.00%; −0.01 pp 30d; as of 6 June 2025
Reported shorts: 304
Shares on issue: 365.968M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Bcal Diagnostics

BCAL Diagnostics Limited is an Australian biotechnology company focused on developing a non-invasive blood test for breast cancer detection. They aim to complement existing imaging technologies and improve screening outcomes. BCAL has a NATA-accredited commercial laboratory and has partnered with ClearNote Health Inc. to expand its diagnostic portfolio.

Company profile →

Bcal Diagnostics (ASX:BDX) has 0.00% of its shares on issue reported as short positions as of 6 June 2025, or about 304 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.12 percentage points. Its highest recorded short interest was 0.36% in July 2021. BDX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads BDX today

Zanger BreakoutWatchScore 32rank 533 of 1942
CAN SLIMWatchScore 10rank 1022 of 1541
Minervini Trend TemplateWatchScore 15rank 1147 of 1716
Crowded-Short BreakoutWatchScore 10rank 901 of 1500
Quality compoundersWatchScore 10rank 1155 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

BDX fundamentals

In the year to 30 Jun 2026, Bcal Diagnostics (ASX:BDX) recorded revenue of A$2.5M and a net loss after tax of A$7.4M. A year earlier it recorded revenue of A$21.6K and a net loss after tax of A$7.2M. Net margin −289.2% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →